AMRX Amneal Pharmaceuticals Holding Co

On July 29, 2022, the Board of Directors (the “Board”) of Amneal Pharmaceuticals, Inc. (the “Company”) appointed Deborah M. Autor to the Company’s Board. Ms. Autor will serve on the Board until the Company’s 2023 annual meeting of stockholders and until her earlier death, resignation successor is duly elected and qualified. The Board affirmatively determined that Ms. Autor is independent under the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and the listing standards of the New York Stock Exchange. Ms. Autor will also serve on the Board’s Conflicts Committee.

From 2019-2021, Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca, where she led regulatory operations, policy and intelligence for AstraZeneca submissions globally. Before joining AstraZeneca, Ms. Autor served at Mylan N.V. from 2013-2019, where she was Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality, where she led Mylan’s largest function globally (5,000 people), overseeing the quality of 60 billion doses of medicine annually. Ms. Autor was a senior leader at the Food and Drug Administration (“FDA”) from 2001-2013, most recently as Deputy Commissioner for Global Regulatory Operations and Policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco and food. Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research, leading enforcement and policy making for compliance with all drug requirements, including, drug approval; current good manufacturing practices (GMP); human subject protection and bioresearch monitoring (GCP); import and export; and recalls. Before joining FDA, Ms. Autor was a Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of the FDA. Ms. Autor received a Juris Doctor, Magna Cum Laude, from Boston University School of Law and a Bachelor of Arts in Psychology from Columbia University, Barnard College.

Ms. Autor will participate in all non-employee director compensation and benefit programs in which the Company’s other non-employee directors participate pursuant to the Company’s Non-Employee Director Compensation Policy.

There are no arrangements or understandings between Ms. Autor and any other persons pursuant to which she was appointed as a member of the Board. There are no family relationships between Ms. Autor and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer. There are no related party transactions involving (within the meaning of Item 404(a) of Regulation S-K promulgated by the SEC) between Ms. Autor and the Company.